Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec 17:6:94.
doi: 10.1186/1756-8722-6-94.

Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation

Affiliations
Review

Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation

Ren Lin et al. J Hematol Oncol. .

Abstract

Viral infections are important causes of morbidity and mortality after allogeneic stem cell hematopoietic transplantation (allo-HSCT). Although most viral infections present with asymptomatic or subclinical manifestations, viruses may result in fatal complications in severe immunocompromised recipients. Reactivation of latent viruses, such as herpesviruses, is frequent during the immunosuppression that occurs with allo-HSCT. Viruses acquired from community, such as the respiratory and gastrointestinal viruses, are also important pathogens of post-transplant viral diseases. Currently, molecular diagnostic methods have replaced or supplemented traditional methods, such as viral culture and antigen detection, in diagnosis of viral infections. The utilization of polymerase chain reaction facilitates the early diagnosis. In view of lacking efficacious agents for treatment of viral diseases, prevention of viral infections is extremely valuable. Application of prophylactic strategies including preemptive therapy reduces viral infections and diseases. Adoptive cellular therapy for restoring virus-specific immunity is a promising method in the treatment of viral diseases.

PubMed Disclaimer

References

    1. Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P, Einsele H, Cordonnier C. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant. 2005;6(9):757–769. doi: 10.1038/sj.bmt.1705140. - DOI - PubMed
    1. Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P. et al.Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007;6(2):125–136. doi: 10.1038/sj.bmt.1705699. - DOI - PubMed
    1. Hale G, Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood. 1998;6(8):3079–3083. - PubMed
    1. Xuan L, Jiang X, Sun J, Zhang Y, Huang F, Fan Z, Guo X, Dai M, Liu C, Yu G. et al.Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation. Transplantation. 2013;6(6):560–566. doi: 10.1097/TP.0b013e31829d38af. - DOI - PubMed
    1. Lv M, Huang XJ. Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go. J Hematol Oncol. 2012;6:10. doi: 10.1186/1756-8722-5-10. - DOI - PMC - PubMed

Publication types

MeSH terms